ReviewImmunotherapy2013
An update on the use of antibodies against the filoviruses.
Review in Immunotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 34 citations in OpenAlex.
- Treatment of Ebola Virus Disease: From Serotherapy to the Use of Monoclonal Antibodies.Antibodies (Basel, Switzerland) · 2025Review
- Efficacy and Immunogenicity of a Recombinant Vesicular Stomatitis Virus-Vectored Marburg Vaccine in Cynomolgus Macaques.Viruses · 2024Article
- Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.Frontiers in immunology · 2021Review
- In silico Designed Ebola Virus T-Cell Multi-Epitope DNA Vaccine Constructions Are Immunogenic in Mice.Vaccines · 2019Article
- Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77.Scientific reports · 2018Article
- Viral metagenomics, protein structure, and reverse genetics: Key strategies for investigating coronaviruses.Virology · 2018Review
- Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus.Frontiers in immunology · 2018Review
- N-Heterocyclic borneol derivatives as inhibitors of Marburg virus glycoprotein-mediated VSIV pseudotype entry.MedChemComm · 2017Article
- Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.Journal of virology · 2016Article
- Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.Journal of virology · 2016Article
- Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies.Journal of virology · 2015Article
- Interferon-Induced Transmembrane Protein-Mediated Inhibition of Host Cell Entry of Ebolaviruses.The Journal of infectious diseases · 2015Article
- Structural and Functional Studies on the Marburg Virus GP2 Fusion Loop.The Journal of infectious diseases · 2015Article
- Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.Molecular pharmaceutics · 2015Article
- Ebola virus outbreak, updates on current therapeutic strategies.Reviews in medical virology · 2015Review
- Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.PLoS pathogens · 2015Article
- Evaluating large-scale blood transfusion therapy for the current Ebola epidemic in Liberia.The Journal of infectious diseases · 2015Article
- Article
- Chemical and Structural Aspects of Ebola Virus Entry Inhibitors.ACS infectious diseases · 2015Article
- Structures of protective antibodies reveal sites of vulnerability on Ebola virus.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Multiple recent, independent studies have confirmed that passively administered antibodies can provide effective postexposure therapy in nonhuman primates after exposure to an otherwise lethal dose of Ebola virus or Marburg virus. In this article, we review composition and performance of the antibody cocktails tested thus far, what is known about antibody epitopes on the viral glycoprotein target and ongoing research questions in further development of such cocktails for pre-exposure or emergency postexposure use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.